Bildkälla: Stockfoto

IRLAB Q2 2024: Clinical progress - Redeye

Redeye returns following IRLAB's Q2 report and recent clinical progress. We reiterate our positive stance to the company and look forward to an exciting H2.

Redeye returns following IRLAB's Q2 report and recent clinical progress. We reiterate our positive stance to the company and look forward to an exciting H2.
Börsvärldens nyhetsbrev
ANNONSER